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Abstract
While high-density lipoprotein (HDL) is known to protect against a wide range of inflammatory stimuli, its anti-inflammatory
mechanisms are not well understood. Furthermore, HDL’s protective effects against saturated dietary fats have not been
previously described. In this study, we used endothelial cells to demonstrate that while palmitic acid activates NF-kB
signaling, apolipoprotein A–I, (apoA-I), the major protein component of HDL, attenuates palmitate-induced NF-kB
activation. Further, vascular NF-kB signaling (IL-6, MCP-1, TNF-a) and macrophage markers (CD68, CD11c) induced by 24
weeks of a diabetogenic diet containing cholesterol (DDC) is reduced in human apoA-I overexpressing transgenic C57BL/6
mice compared to age-matched WT controls. Moreover, WT mice on DDC compared to a chow diet display increased gene
expression of lipid raft markers such as Caveolin-1 and Flotillin-1, and inflammatory Toll-like receptors (TLRs) (TLR2, TLR4) in
the vasculature. However apoA-I transgenic mice on DDC show markedly reduced expression of these genes. Finally, we
show that in endothelial cells TLR4 is recruited into lipid rafts in response to palmitate, and that apoA-I prevents palmitate-
induced TLR4 trafficking into lipid rafts, thereby blocking NF-kB activation. Thus, apoA-I overexpression might be a useful
therapeutic tool against vascular inflammation.
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Introduction
Low levels of high-density lipoprotein (HDL) cholesterol are
associated with increased risk of coronary artery disease and
major cardiovascular events. HDL-raising strategies are being
evaluated for the prevention and treatment of coronary artery
disease. HDL may mediate atheroprotective effects by stimula-
tion of eNOS-dependent NO production, mediation of endo-
thelial repair, and promotion of cholesterol efflux from
macrophage foam cells [1,2,3,4,5]. In addition, HDL possesses
powerful anti-inflammatory and anti-atherogenic properties by
decreasing expression of cytokine-stimulated adhesion molecules,
such as ICAM-1, VCAM-1 and E-selectin-1 in endothelial cells
[6,7], and attenuating expression of monocyte chemotactic
protein, MCP-1 in the vasculature [8]. Since HDL is known to
exert anti-inflammatory effects against a wide range of
inflammatory agents such as oxidized low-density lipoproteins
(LDL) [9] oxidized phospholipids [10] and 7-ketocholesterol
[11], we sought to investigate whether HDL attenuates vascular
inflammatory responses mediated by saturated fats such as
palmitate.
Apolipoprotein A–I (apoA-I), the major protein constituent of
HDL is able to recapitulate many protective functions of HDL
[2], [3], [12], [13]. One mechanism by which apoA-I is believed
to be anti-inflammatory is by mediating cellular cholesterol
efflux through ABCA1, an ATP-binding transporter in macro-
phages [14,15]. Several studies have demonstrated apoA-I to be
anti-inflammatory in different animal models: in vivo apoA-I
infusion was shown to be protective to rabbits when subjected to
acute inflammation [16]. Also, apoA-I mimetic peptides, D-4F
and L-4F, reduced vascular inflammation induced by strepto-
zotocin injection in Sprague-Dawley rat [17] and improved
insulin sensitivity in a mouse model of diabetes and obesity [18].
Based on these findings, we sought to study the role of HDL,
and its predominant protein component, apoA-I on saturated
fatty acid-induced inflammation in endothelial cells. Further, we
hypothesized that apoA-I overexpressing transgenic mice would
be protected from inflammatory effects of a high-fat, athero-
genic diet.
Moreover our in vitro studies with endothelial cells suggest a
mechanism by which apoA-I protein exerts the protective
functions of HDL. ApoA-I prevents TLR4 migration into lipid




Wild type C57BL/6 and apoA-I transgenic mice were
purchased from the Jackson labs. All animals were maintained
in a temperature-controlled facility with a 12 hour light-dark
cycle. WT (n=7 on DDC and n=5 on chow) and apoA-I
transgenic mice (n=7 on DDC and N=7 on chow) of C57BL/6
background at 6–8 weeks of age were put on a diabetogenic diet
containing cholesterol at 0.15% w/w (abbreviated as DDC,
BioServ F4997; the diabetogenic diet provides 35.5% calories as
fat and 36.6% as carbohydrate) or a standard rodent chow diet
(providing 4% calories as fat) for 24 weeks [19]. At the end of the
study period, the mice were sacrificed and the thoracic aortae were
collected in RNAlaterH (Ambion, Austin, TX) and stored at
220uC until used for RNA extraction. All experimental
procedures were undertaken with approval from the Institutional
Animal Care and Use Committee of the University of Washing-
ton.
Reagents
Human ICAM-1 antibody, and Human IL-6 ELISA kit was
purchased from R&D systems. HDL was prepared as previously
described [20]. ApoA-I was purchased from Academy Bio-medical
Company, Inc, Houston, TX. M bCD (methyl-beta-cyclodextrin)
and cyclodextrin-cholesterol (CD-cholesterol) were purchased
from Sigma-Aldrich. Antibodies against Caveolin-1 and phos-
phorylated-p65 subunit of NF-kB (used at 1:1000 dilution) were
obtained from Cell Signaling. TLR4 antibodies (used at 1:500) and
Alexa-594-conjugated Cholera-Toxin-B (CTx-B) were obtained
from Invitrogen. Anti-CTx-B antibodies were obtained from
Calbiochem. Antibodies against GAPDH (used at 1:2000) was
obtained from Santa Cruz Biotechnology. Palmitic acid (C16:0)
fatty acids were obtained from Alltech Associates Inc., and BSA
(bovine serum albumin, free-fatty acids (FFA)-free) was purchased
from Roche. FFA were dissolved in 0.1 mol/L NaOH at 70uC
and then complexed with 10% BSA at 55uC for 10 minutes. Stock
solutions of 5 mmol/L FFA with 10% BSA and 10% BSA were
prepared a day before the experiments and diluted in endothelial
cell culture media to achieve a final palmitate concentration of
100 mmol/L as described previously [21]. Optiprep (60%
Iodixanol) was purchased from Sigma-Aldrich and used to
generate a step gradient consisting of 5%, 30% and 40%.
Cell culture. Human microvascular endothelial cells
(HMEC) were purchased from Invitrogen-Cascade Biological
and were cultured as previously described [21]. Bovine aortic
endothelial cells (BAEC) were purchased from Clonetics and
cultured as previously [22]. IL-6 ELISA was performed as per the
instructions of the manufacturers. Western blotting was performed
with equal amounts of total protein for each condition and
experiment as described [21].
Isolation of lipid rafts using Optiprep gradient
centrifugation. Lipid raft isolation was performed as follows:
BAEC or HMEC were grown to confluence in 10 cm dishes. They
were treated with the various agents (palmitic acid, with or without
pretreatment with MbCD or apoA-I in 10% lipid-deficient serum
in DMEM) for the designated durations and doses. They were
then washed, the cells trypsinized, washed twice with phosphate
buffered saline (PBS), resuspended in 133 ml of cell lysis buffer at
4uC. Lysis buffer comprises of 1% Triton-X-100, 25 mM Tris
HCl, pH 7.4, 5 mM EDTA, 1 mM sodium orthovanadate,
100 mM DTT, 200 mM PMSF, 10 mg/ml and protease
inhibitors. The cells were sonicated to ensure lysis. Next, 133 ml
of the lysate was mixed with 267 ml of the 60% optimix solution
(Sigma) to form the bottom most layer of the gradient in the
ultracentrifuge-compatible microfuge tube. The next layer was
generated using 700 ml of the 30% optimix solution and the final
layer was composed of a 5% optimix solution. The microfuge
tubes were spun in a tabletop ultracentrifuge for 18 hours at
100,000 g at 4uC in a TLA-55 bucket in a Beckman rotor. The
gradient was divided into 10 equal parts and fractions 2-5
represented the lipid raft fraction and the fractions 6–9
represented the non-lipid raft fraction. Protein concentration was
determined using Pierce BCA protein assay (Piece, Rockford, IL).
The pooled fractions were resuspended in sample lysis buffer
boiled for 5 minutes and stored in 220uC till analyzed by western
blotting.
Western blotting. SDS gel electrophoresis was performed
using a 4% by 20% gradient gel. Quantification of Western blots
was performed using Image J Processing and Analysis (NIH).
Quantitative RT-PCR Analyses. RNA was extracted using
RNAeasy kit (Qiagen). For gene expression analysis, real-time-
PCR reactions were performed using TaqMan Gene Expression
Analysis from Applied Biosystems as described previously [21] and
normalized to GAPDH levels. Human ICAM-I, or the Mouse IL-
6, MCP-1, TNF-a, CD68, CD11c, Caveolin-1, Flotillin-1, TLR4
and TLR2 RT-PCR primer pairs were purchased from Applied
Biosystems.
Cholesterol efflux measurement. BAEC were labeled with
1 mCi/ml of
3[H] cholesterol (PerkinElmer Life Sciences) for
24 hours. The cells were washed and then incubated with or
without human apoA-I (10 mg/ml) for 8 hours in DMEM/BSA.
Cholesterol efflux was measured by counting
3[H] in the medium
and the cell extracts. ApoA-I-mediated cholesterol efflux was
calculated as the percent total [
3H]cholesterol released into
medium after subtraction of values obtained in the absence of
apoA-1 [14].
Immunofluorescent microscopy of lipid
rafts. Endothelial cells were grown on coverslips within a 6-
well plate at the density of 200,000/well. After overnight growth,
they were treated with either HDL (50 mg/ml) or apoA-I (50 mg/
ml) for 16 hours or M bCD (1 mM for 30 mins), or CD-
cholesterol (40 mg/ml for 1 hour). After the respective treatment
times, they were washed multiple times before being treated with
Alexa-594 conjugated to Cholera-toxin-B (CTx-B, 1 mg/ml) at
4uC for 10 minutes in the dark. They were washed 3 times and
incubated with anti-CTx-B antibodies (4 mg/ml, Calbiochem) for
15 mins, washed with PBS thrice, and treated with DAPI (1 ng/
ml), followed by washing with PBS 3 more times. Subsequently,
cells were fixed in 4% paraformaldehyde in PBS for 15 minutes.
The coverslips with the cells were then placed on microscopic glass
slides, which were treated with Biomeda’s aqueous mounting
medium containing anti-fading solution. For imaging, an Olympus
fluorescence microscope was used and images collected using
appropriate filter sets. The quantification of the fluorescent
intensities was done by the NIS-elements software. The
fluorescent intensities of about 30-50 cells were measured in
each experiment, and expressed as arbitrary fluorescence units.
Statistical analysis. All results are represented as mean 6
SEM. Results were analyzed using a 2-tailed Student’s t- test or
one- or two-way ANOVA, where appropriate using Graphpad
Prism software. A Bonferroni post hoc analysis was done to
compare mean values between groups. P,0.05 was considered to
be significant and marked *, P,0.01 was marked **, p,0.001 was
marked ***.
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Diabetogenic diet-induced vascular inflammation is
reduced in apoA-I transgenic mice
We first asked whether overexpression of apoA-I, an integral
component of HDL, would reduce high-fat, high-sucrose diet-
dependent vascular inflammation [23]. WT C57BL/6 and
apoA-I transgenic mice were maintained on a normal chow diet
or a diabetogenic diet (DD) plus 0.15% cholesterol containing
diet (DDC) for 24 weeks. At the end of the study period, mice
were sacrificed, thoracic aortae were carefully removed and
cleaned of adhering adipose tissue. As expected, gene expression
of NF- kB dependent signaling (IL-6, MCP-1, TNF-a)a n d
monocyte/macrophage/dendritic cell markers (CD68 and
CD11c) increased in response to 24 weeks of DDC, whereas,
overexpression of human apoA-I in vivo attenuated these
responses (Figure 1A).
Lipid rafts, cholesterol-rich microdomains in the plasma
membranes, serve as recruiting platforms for many immune
receptors in response to their cognate ligands involved in
inflammatory signaling (eg. TLR4, TNF-receptor) [24], [25].
Perturbation of lipid raft composition or altering the number of
rafts is known to affect inflammatory signaling [24], [26], so we
next asked whether apoA-I overexpression is associated with
alterations in lipid rafts. The DDC diet increased lipid raft markers
(caveolin-1, flotillin-1), a response not seen in apoA-I transgenic
mice (Figure 1B). Thus apoA-I overexpression is associated with
reduced lipid raft markers.
TLR2 and TLR4 are recruited into lipid rafts in response to
lipoproteins and LPS respectively to cause NF-kB activation
[24], [26], [27]. Thus, we assessed the gene expression levels of
the TLR2 and 24 in our diet-induced obesity (DIO) studies and
found that while DDC significantly elevated the levels of
expression of these inflammatory mediators, the apoA-I
transgenic animals had markedly reduced expression
(Figure 1B). These data collectively suggest that apoA-I
overexpression is protective towards vascular inflammation by
reducing NF-kB mediated inflammatory mediators such as IL-6,
MCP-1, TNF-a, caveolin-1, flotillin-1, TLR2 and TLR4. ApoA-
I overexpression also reduced immune cell markers, CD68 and
CD11c expression, presumably due to reduced expression of
recruiting chemokines such as MCP-1. We did not see significant
changes in M2 markers such as IL-10 and Arginase-1 (data not
shown).
Figure 1. ApoA-I overexpression attenuates the effect of DDC on vascular inflammation and lipid raft markers. C57BL/6 (WT) or apoA-I
transgenic mice were fed a standard (chow) or a DDC diet for 24 weeks and gene expression from isolated thoracic aortic tissues were assessed by
quantitative RT-PCR. A. Fold differences between groups were calculated for MCP-1, IL-6 and TNF-a (NF-kB dependent signaling) CD68, CD11c
(monocyte markers) relative to GAPDH. B. Fold differences between groups were calculated for Caveolin-1 and Flotillin-1 (lipid raft markers), TLR2
and TLR4 (Toll-like receptors) relative to GAPDH. *P,0.05, **p,0.001, n=4–7 for each condition.
doi:10.1371/journal.pone.0033917.g001
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or apoA-I in endothelial cells in vitro
HDL/apoA-I reduces NF-kB activation mediated by many
stimuli such as LPS, TNF-a, and oxidized LDL [6], [7], [13],
[28]. We next asked whether HDL/apoA-I would similarly reduce
palmitate-dependent activation of endothelial NF-kB. Human
microvascular endothelial cells (HMECs) were pretreated with
50 mg/ml of HDL or apoA-I (50 mg/ml) for 16 hours, washed and
subsequently treated them with 100 mM of palmitate for 3 hours.
Pretreatment with either HDL or apoA-I significantly reduced
palmitate-dependent increases in the expression of ICAM-1, and IL-
6 cytokine levels compared to the vehicle-treated cells (Figure 2A,
B). These observations were also found in a model of large vessel
endothelial cells (BAEC). Pretreatment with apoA-I or HDL
attenuated palmitate-mediated NF-kB activation, as assessed by
phosphorylation of the p65 subunit of NF-kB( Figure 2C).
Therefore, HDL/apoA-I is able to attenuate palmitate-mediated
NF-kB-dependent inflammatory responses in endothelial cells.
Palmitate induces TLR4 migration into lipid rafts
It was shown previously that LPS-induced TLR4 activation is
initiated by recruitment of TLR4 into lipid rafts, a critical and
early step in the inflammatory signaling process [24], [25]. Since
TLR4 is necessary for palmitate-mediated-activation of NF-kB
[21], we next examined whether palmitate increases recruitment
of TLR4 into lipid rafts. HMEC were treated with palmitate
(100 mM) for 1, 2, 3, and 6 hours and the raft and non-raft
fractions were isolated using Optiprep gradient centrifugation.
Compared to BSA alone treated HMEC (control), palmitate-BSA
increases TLR4 migration into isolated lipid rafts by 3–6 hours
Figure 2. HDL or apoA-I attenuates palmitic acid dependent NF- kB signaling in endothelial cells. HMEC were pretreated with vehicle
(labeled as control) or with human HDL (50 mg/ml) or ApoA-1 (50 mg/ml) for 16 hours, washed and then either treated with palmitate complexed
with BSA (100 mM) for 3 hours or treated with BSA alone. A–B. ICAM-1 mRNA expression was analyzed using quantitative RT-PCR. IL-6 cytokine levels
in supernatants were assessed by ELISA (n=3). Data represents mean 6 SD and *p,0.05,**p,0.01,***p,0.005. C. BAEC lysates were prepared after
pretreatment with apoA-I/HDL and phopho-P65 levels were assessed by Western blot.
doi:10.1371/journal.pone.0033917.g002
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enriched with the caveolin-1 protein compared to the non-raft
fractions (Figure 3A). The 3 hour time-point for TLR4 migration
corresponds to the maximal NF-kB activation time-point as seen
previously [21], [23]. Palmitate similarly recruited TLR4 into lipid
rafts in BAEC (data not shown).
Lipid raft integrity is important for palmitate-induced
TLR4 mediated NF-kB activation
We next asked whether the structural integrity of the lipid rafts
is required for palmitate-induced TLR4-mediated endothelial cell
activation. Methyl-beta-cyclodextrin (MbCD), a cholesterol-efflux-
ing agent, disrupts the integrity of the lipid rafts by reducing the
cholesterol content in the lipid rafts [24]. HMEC/BAEC were
pretreated with vehicle or exposed to 5 mM MbCD for 1 hour
prior to exposure to palmitate (100 mM) for 3 hours. Pretreatment
with MbCD reduced palmitate-mediated phosphorylation of p65
subunit (Figure 4A, B) and reduced the recruitment of TLR4 into
the lipid rafts (Figure 4C). Thus, functional lipid rafts are
required for the palmitate induced TLR4 mediated NF-kB
activation in endothelial cells.
ApoA-I reduces lipid raft abundance and reduces TLR4
migration into lipid rafts
ApoA-I is known to cause cholesterol efflux from macrophages
[14], [15]. Previously, Murphy and coworkers showed that HDL/
apoA-I reduces lipid raft content in monocytes and neutrophils as
assessed by GM1 ganglioside staining, a component of lipid rafts
[29], [30–31]. We next asked whether apoA-I exerts its anti-
inflammatory effect in endothelial cells via cholesterol removal,
thereby disrupting lipid raft signaling. Treatment with purified
human apoA-1 increased cholesterol levels in the media,
suggesting that apoA-1 enhances cholesterol endothelial efflux
(Figure 5A). Next we asked whether apoA-I induced cholesterol
efflux in endothelial cells is associated with a reduction in lipid raft
content. We tested this hypothesis by direct visualization of total
lipid rafts by fluorescence microscopy using labeled cholera toxin-
B (CTx-B), which binds specifically to GM1 ganglioside, a lipid
raft marker. We found that cholesterol- depleting agents such as
MbCD, apoA-I or HDL treated endothelial cells had lower lipid
raft abundance relative to untreated endothelial cells. In contrast,
cholesterol-loaded cells (by CD-cholesterol) have higher lipid raft
content (Figure 5B), which was previously shown to be associated
with enhanced NF-kB activation [30]. Collectively these data
suggest that apoA-I exerts an indirect anti-inflammatory effect by
virtue of reducing the lipid raft content by cholesterol removal.
We next pretreated BAEC with apoA-I (100 mg/ml) for
16 hours in lipid-free serum containing media, before treating
with palmitate (100 mM) for three hours. Pooled lipid raft fractions
were assessed for TLR4 and caveolin-1 protein levels by Western
blot analysis. Palmitate induced TLR4 recruitment was abrogated
by apoA-I pretreatment (Figure 5C). Thus, apoA1 reduces
palmitate-mediated TLR4 recruitment into lipid rafts by increas-
Figure 3. TLR4 is recruited into lipid rafts in response to palmitate. A. BAEC were treated with BSA alone (control) or palmitate/BSA (100 mM)
for 1, 2, 3 and 6 hours. Lipid rafts were isolated by Optiprep gradient centrifugation and the raft(depicted as ‘R’) and non-raft fractions(depicted as
‘NR’) were pooled. Cell lysates were assessed for TLR4 and caveolin-1 protein levels by Western blot. Representative immunoblot from 3 independent
experiments is shown. B. Densitometric quantitations of western blots comparing the band intensities of TLR4 in the raft fraction to caveolin-1 in the
same raft fraction(n=5). C. Densitometric quantitations of Western blots comparing the band intensities of TLR4 in the raft fraction to total TLR4 (lipid
raft and non-raft fraction) are shown.
doi:10.1371/journal.pone.0033917.g003
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consistent with studies that showed human apoA-I [32] or apoA-I
mimetic peptide, 4F [33] reduces TLR4 expression on the cell
surface of endothelial cells and monocytes.
Discussion
In the setting of diabetes and obesity, elevated free fatty acids
are associated with the pathogenesis of inflammation in the
vasculature and peripheral tissues. At a molecular level, free fatty
acids activate IKK-k/NF-kB pathway via TLR4 leading to
increased expression of adhesion molecules such as ICAM-1 and
VCAM-1, and release of proinflammatory cytokines such as IL-6
and TNF-a. While, cholesterol and dietary saturated fats increase
vascular inflammation, HDL and its constituent protein, apoA-I
have been shown to reduce inflammatory signaling [1], [4], [13].
In the present study, we examined the ability of HDL or apoA-I,
to reduce these vascular inflammatory responses. We found that,
both, HDL or apoA-I, attenuates palmitate-dependent NF-kB
activation in endothelial cells in vitro by reducing TLR4 migration
into lipid rafts. Similarly, we found that unlike its WT
counterparts, apoA-I transgenic mice were protected from
diabetogenic diet-induced vascular inflammation.
Our study suggests a possible mechanism by which apoA-I
exerts its anti-inflammatory effects through modification of lipid
rafts and secondary effects on TLR4 and NF-kB signaling.
Caveolin-1 is a fundamental structural protein of the caveolae/
lipid raft membrane domains [34], [35]. It is known to bind to
cholesterol, interact with and negatively regulate endothelial nitric
oxide synthase (eNOS) and stimulate the expression of proathero-
genic molecules such as CD36, a fat transporter, and VCAM-1
[34]. Caveolin-1 levels have been shown to be elevated in the aorta
of rabbits fed a high-fat diet [36] and is elevated in response to
endotoxin via an NF-kB-dependent pathway in endothelial cells
[37], [38]. Ablation of endothelial caveolin-1 protects ApoE2/2
mice (a mouse model of atherosclerosis), from developing
atherosclerosis [34], [35]. Consistent with these observations, our
study shows that WT mice fed a high-fat diet have higher levels of
Caveolin-1 expression and markedly increased vascular inflam-
mation compared to chow-fed WT mice. However in the human
apoA-I transgenic mice fed a high-fat diet, Caveolin-I expression is
significantly reduced with a parallel reduction in vascular
inflammation. There is also a similar reduction in Flotillin-1
expression, another critical structural component of the planar
lipid rafts [26]. Together these observations suggest that lipid rafts
may play a fundamental role in high-fat induced vascular
inflammation, and that apoA-I may affect diet-induced inflam-
mation by either directly or indirectly altering lipid rafts. Our
observation that apoA-I effluxes cholesterol from the plasma
membranes of BAEC further supports this model since cholesterol
depletion can lead to lipid raft disruption and hence reduced
inflammatory signaling.
Our in vivo data also show that apoA-I is associated with
decreased TLR2 and 24 expression. It has been well-established
that expression of TLRs play an important role in innate immunity
butalsoinmediating NF-kB-induced-inflammationinDIOmodels.
Previously, Tall and coworkers showed that macrophages of mice
lacking ABC transporters haveelevated surfaceexpression of TLRs,
specifically TLR4/MD-2, associated with increased inflammation
as compared to macrophages from WT mice [30]. In rodent DIO
models, TLR2 and 24 expression levels were found to be
augmented in adipose tissue [39], and vasculature [40]. These
findings support ourfindingthat TLR2 and 24 expression wereup-
regulated in DDC-fed WT mice while the apoA-I transgenic mice
on DDC were protected from this effect.
Figure 4. Disruption of lipid raft integrity by MbCD reduces palmitate-mediated NF- kB signaling and TLR4 migration in endothelial
cells. HMEC cells were pretreated with vehicle or MbCD (5 mM/1 hr) (to disrupt lipid raft integrity) and then stimulated with palmitate/BSA (100 mM)
for 3 hr. Cell lysates were assessed by Western blot with an anti-phospho-p65 antibody (n=3). B. Experiments were repeated in BAEC (n=3). C. Lipid
rafts were isolated and the non-raft and lipid-raft fractions pooled, and assessed for TLR4 and caveolin-1 protein level by Western blot. Representative
immunoblots from 3 independent experiments are shown.
doi:10.1371/journal.pone.0033917.g004
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TLR4 and lipid rafts in a high-fat induced inflammatory model. We
previously showed that the mechanism by which palmitate causes
endothelial dysfunction involves TLR4-mediated induction of the
inflammatory NF-kB pathway in endothelial cells [21]. In this
report, we extend our observation by showing that in endothelial
cells TLR4 is recruited into lipid rafts in response to palmitate. Our
finding that saturated fat exemplified by palmitate causes TLR4
recruitment into lipid rafts to induce inflammatory signaling is
consistent with a earlier study by Hwang and coworkers, who
demonstrated this phenomenon in macrophages [41].
We further demonstrate that apoA-I disrupts the interaction
between TLR4 and lipid rafts by impairing recruitment of TLR4
into the rafts. Since apoA-I is known to cause cholesterol efflux out
of cell membranes, we sought cholesterol acceptors also known to
remove cholesterol from cells to see if they would have similar
effects as apoA-I. Indeed, MbCD reduced palmitate-induced
TLR4 recruitment into lipid rafts and NF-kB activation suggesting
that palmitate induced NF-kB activation requires functional lipid
rafts and cholesterol efflux can inhibit this process.
Finally we looked downstream of TLR4 signaling and studied
apoA-I’s effects on NF-kB activation. TLR4 activates NF-kB
induced inflammation in endothelial cells. We show that apo-AI
addition to endothelial cells prevents TLR4-mediated NF-kB
activation. Our study is consistent with the other studies, which
show that treatment of human monocytes with apoA-I or apoA-I
mimetic 4F leads to reduced surface expression of TLR4 and
CD11c [33]. Another study found that there is reduction in
chemokines such as MCP-1, and chemokine receptors such as
CCR2 in atherosclerotic plaques of ApoE2/2 mice in response
to apoA-I injections [42].
In conclusion, apo-AI overexpression attenuates high fat
mediated-vascular inflammation by reducing the expression of
chemokines and cytokines in vivo. Similarly, in endothelial cells,
HDL/apo-AI attenuates palmitate-induced NF-kB activation by
scavenging cholesterol from plasma membrane domains, thereby
reducing total lipid raft content, decreasing TLR4 migration into
lipid rafts resulting in reduced TLR4 signaling.
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Figure 5. Apo-AI increases endothelial cholesterol efflux, reduces lipid raft content and TLR4 migration into lipid rafts. A. BAECs
were labeled with 1 mCi/ml of
3[H] cholesterol (PerkinElmer Life Sciences) for 24 hours. The cells were washed and then incubated with vehicle or
human ApoA-1 (10 mg/ml) for 8 hours in DMEM/BSA. Cholesterol efflux was measured by counting
3[H] in the medium and the cell extracts. ApoA-I-
mediated cholesterol efflux was calculated as the percent total [
3H]cholesterol released into medium after subtraction of values obtained in the
absence of apoA-I (n=3–7), ***p,0.001 indicates significance. B. Lipid raft staining was done and visualized by fluorescence microscopy, using
fluorescent cholera-toxin-B, which binds specifically to GM1 ganglioside. Positive control (increase cholesterol content: CD-cholesterol) and negative
control (reduce cholesterol content: (MbCD)) were used. Endothelial cells were treated with either HDL or apoA-I (50 mg/ml) for 16 hours, MbCD
(1 mM) or CD-cholesterol (20 mg/ml). The data has been represented as relative fluorescent intensities compared to untreated cells. In each
experiment, 30–50 cells were counted (n=2). C. BAEC were pretreated with apoA-I for 16 hours prior to treating with palmitic acid for three hours.
The cells were then washed with PBS, trypsinized, lipid raft and non-raft fractions isolated. The pooled raft and non-raft fractions were assessed for
TLR4 and Caveolin-1 proteins by Western blot. Representative immunoblot from 4 independent experiments is shown(n=4).
doi:10.1371/journal.pone.0033917.g005
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